Mayne Pharma Group Limited (FRA:HG6)
Germany · Delayed Price · Currency is EUR | Market Cap | 128.66M -61.9% |
| Revenue (ttm) | 231.28M -1.6% |
| Net Income | -47.28M |
| EPS | -0.60 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 0 |
| Open | 1.430 |
| Previous Close | 1.500 |
| Day's Range | 1.430 - 1.430 |
| 52-Week Range | 1.130 - 4.000 |
| Beta | n/a |
| RSI | 64.68 |
| Earnings Date | May 22, 2026 |
About Mayne Pharma Group
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women’s Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers. It also distributes specialty pharmaceutical products in the dermatology, women’s health, and in... [Read more]
Financial Performance
In fiscal year 2025, Mayne Pharma Group's revenue was 408.10 million, an increase of 5.07% compared to the previous year's 388.40 million. Losses were -93.84 million, -46.14% less than in 2024.
Financial numbers in AUD Financial StatementsNews
Termination of Proposed Acquisition of Mayne Pharma
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December 2025 it served a notice on Mayne Pharma ...
Australia Blocks U.S.-Based Cosette's $387.2 Million Takeover of Mayne Pharma
Australia's government said it would block a $387.2 million takeover of Mayne Pharma by U.S. company Cosette Pharmaceuticals on national security grounds, citing a need to protect critical medical sup...
Australia blocks Cosette Pharmaceuticals bid to buy Mayne Pharma
Australia on Friday blocked a A$672 million ($433 million) buyout offer for Mayne Pharma from U.S. drugmaker Cosette Pharmaceuticals, citing national interest.
Australia's Mayne Pharma falls as treasurer considers blocking Cosette's $437 million bid
Australia's Mayne Pharma said on Friday it had received a letter from its potential acquirer, Cosette, indicating that the country's treasurer is considering blocking the A$672 million ($436.67 millio...
Cosette's attempt to drop $438 million Mayne Pharma deal denied by court
An Australian court has moved to prevent U.S. drugmaker Cosette Pharmaceuticals from abandoning its A$672 million ($437.6 million) acquisition of Mayne Pharma , the ASX-listed company said on Thursday...
Mayne Pharma slumps 30% as Cosette threatens to scrap $432 million deal
Shares of Mayne Pharma plunged 30% on Wednesday after U.S.-based Cosette Pharmaceuticals initiated a review of its A$672 million ($432.1 million) acquisition, citing a "material adverse change" in the...
FEDERAL CONTRACEPTION PROPOSAL TO EXPAND ACCESS AND AFFORDABLE COVERAGE PAVES A STRONGER PATH FOR MAYNE PHARMA'S GROWTH IN WOMEN'S HEALTH
Proposed Ruling Aims to Eliminate Out-of-Pocket Costs for Contraception, Enhancing Access for Women in the United States ADELAIDE, Australia and RALEIGH, N.C. , Nov. 4, 2024 /PRNewswire/ -- Mayne Phar...
Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringement
Mayne Pharma has filed a patent infringement lawsuit against Indian drugmaker Sun Pharma in a U.S. court, the Australian drugmaker said on Thursday.